| Daily Updates | View All |
|
A genetic therapy for Parkinson's disease can now begin Phase 2 clinical trials after a go-ahead from the FDA. Read how the United States Food and Drug Administration is working to get beneficial Parkinson's drugs to market faster. A promising Parkinson's disease drug fails to win approval from the FDA. Istradefylline will not be coming to pharmacies in the near future. A new delivery method of an old Parkinson's disease medication has reportedly been granted fast track designation by the FDA. This is good news for people looking for improvements in Parkinson's disease care. Aug '0722 Clinical Trial for Parkinson's Medication Will Repeat With Lower Doses After Disappointing ResultsIf you watch the news about new drugs that may come available for Parkinson's disease, you have read about safinamide. We told you about safinamide back in May, when some encouraging research was presented at the Annual Meeting of the American Academy of Neurology. When combined with a dopamine agonist or levodopa, safinamide appears to help people. It appeared to lessens motor symptoms and improves activities of daily living. Patients in the clinical trial also reported improvement in cognitive performance—a sought after effect.
The ice cube I am watching GENEVA, Switzerland - Merck Serono S.A. announced this week that Phase III data on Safinamide, a new agent in late-stage development for the treatment of Parkinson's disease symptoms, was presented by Professor Fabrizio Stocchi at the American Academy of Neurology's 59th Annual Meeting in Boston, Massachusetts. The data comes from a 6-month (24 week), randomized, double blind, placebo-controlled, international trial. There are a few promising treatments for late stage Parkinson's disease that we all hope make if through the research pipeline, like Duodopa. (If you are willing to travel to Europe, you can get it now.) There is another treatment that just entered phase II of clinical trials called CERE-120. We wrote a blog entry about CERE-120 last fall, when it completed phase I clinical trials. Recently Ceregene, CERE-120's manufacturer, began recruiting for it's phase II clinical trial. It plans to enroll 51 patients with advanced Parkinson's disease at nine medical centers in the United States. |
|
| Solutions | View All |
|
Get 33% off your first order of Vitaline CoQ10!
Get a break on the cost of your prescription medication
Get a $500 discount on a Theracycle You are never too old to benefit from exercise Stop falls - Increase mobility - Overcome freezing episodes You can address your balance problem and overcome freezing episodes by using advanced walking aids. 
|
|
